-
公开(公告)号:EP0619316A1
公开(公告)日:1994-10-12
申请号:EP94105380.3
申请日:1994-04-07
发明人: Shimada, Junichi , Kuwabara, Takashi , Yasuzawa, Tohru , Magara, Hiroshi , Nonaka, Hiromi , Kusaka, Hideaki , Suzuki, Fumio
IPC分类号: C07D473/04 , A61K31/52
CPC分类号: C07D473/04 , Y10S514/869
摘要: There is provided a novel xanthine Compound(I)
wherein R¹ and R² are the same or different and each represent hydroxy-substituted, oxo-substituted or unsubstituted lower alkyl, Y is a single bond or alkylene, and Q is
wherein R³ and R⁴ are the same or different and each represent hydrogen or hydroxy, n is 0 or 1; provided that when both of R³ and R⁴ are hydrogen, at least one of R¹ and R² is hydroxy-substituted or oxo-substituted lower alkyl; or a pharmaceutically acceptable salt thereof.
The xanthine compound has adenosine A₁ receptor antagonizing activity, and thus shows diuretic effect, renal-protecting effect, bronchodilatory effect, cerebral function improving effect and anti-dementia effect.摘要翻译: 提供了一种新颖的黄嘌呤化合物(I)
其中R 1和R 2相同或不同,各自表示羟基取代的,取代或未取代的低级烷基,Y是单键或亚烷基 且Q为 ,其中R 3和R 4相同或不同,各自表示氢或羟基,n为0或1; 条件是当R 3和R 4都是氢时,R 1和R 2中的至少一个是羟基取代的或氧代取代的低级烷基; 或其药学上可接受的盐。 黄嘌呤化合物具有腺苷A1受体拮抗活性,因此具有利尿作用,肾保护作用,支气管扩张作用,脑功能改善作用和抗痴呆作用。 -
公开(公告)号:EP0619316B1
公开(公告)日:1998-08-12
申请号:EP94105380.3
申请日:1994-04-07
发明人: Shimada, Junichi , Kuwabara, Takashi , Yasuzawa, Tohru , Magara, Hiroshi , Nonaka, Hiromi , Kusaka, Hideaki , Suzuki, Fumio
IPC分类号: C07D473/04 , A61K31/52
CPC分类号: C07D473/04 , Y10S514/869
-